Köpfe

Hans-Uwe Simon

Prof. Dr. med. Dr. h.c. mult. Simon
Titel: Prof. Dr. med. Dr. h.c. mult.
Aktuelle Position: Präsident
Fachbereich: kein
Dienstadresse:
Medizinische Hochschule Brandenburg
Campus Neuruppin
Fehrbelliner Str. 38
16816 Neuruppin
Diensttelefon: +49 3391 39-14110
Dienst-E-Mail: hans-uwe.simon@mhb-fontane.de
 
In der MHB seit: 01.09.2021
Curriculum Vitae

Education:

Friedrich Schiller University Jena (Germany):
1980-1986 Medical School (magna cum laude)
1984 M.Sc.; Dipl.-med. (summa cum laude)
1985 M.D.; Dr. med. (summa cum laude)
1990 Specialization in Immunology (Facharzt)

University of Toronto (Canada), Mount Sinai Hospital and Toronto
General Hospital, Departments of Molecular Biology and Immunology:
1990-1992 Postdoctoral fellowship

University of Zurich (Switzerland):
1996 Venia legendi; PD Dr. med.

University of Jerusalem (Israel), Hadassah Medical School, Department of Pharmacology:
1996-2001 Ph.D.

University of Bern (Switzerland):
2000-2005 Specialization in Clinical Immunology (FAMH)

Medical Licensure:

MD No. 71/86, Gera 1986

Professional Positions in Medical Research and Teaching:

1992-2000

University of Zurich, Swiss Institute of Allergy and Asthma Research, Principle Investigator, Head of Asthma Research

1996-2000

Swiss Institute of Allergy and Asthma Research, Deputy Director, Principal Investigator

2000-2021

University of Bern, Director of the Department of Pharmacology, Principal Investigator, Full-Professor

2012-2016

University of Bern, Vice-Dean for Research, Faculty of Medicine

2016-2020

University of Bern, Dean, Faculty of Medicine

2018-today

Medical University of Moscow – Department of Clinical Immunology and Allergology, Sechenov University, Moscow  (Russia), Full-Professor

2021-today

Kazan Federal University – Institute of Fundamental Medicine and Biology, Kazan (Russia), Principal Investigator, Visiting Professor

2021-today

University of Bern, Deputy Director of the Department of Pharmacology, Principal Investigator, Full-Professor

2021-today

Brandenburg Medical School, Neuruppin, Germany, President

Additional Administrative and Advisory Posts:

  • Treasurer, European Cell Death Society (ECDO), 2000-2005
  • Member of the Executive Committee of the European Academy of Allergology and Clinical Immunology (EAACI), 2001-2003
  • Member of the Central Committee of the Union of the Swiss Societies for Experimental Biology (USGEB/USSBE), 2002-2007
  • Member of the Scientific Advisory Board, Society in Science: The Branco Weiss Fellowship, ETH Zürich, 2002-2008
  • President, Swiss Society of Pharmacology and Toxicology (SSPT), 2004-2007
  • Member of the Board, Section of Immunology of the European Academy of Allergology and Clinical Immunology (EAACI), 2003-2007
  • Member of the Ethics Committee, European Academy of Allergology and Clinical Immunology (EAACI), 2003-2007
  • Member of the Scientific Commission, Research Foundation of the University of Bern, 2005-2016
  • President, Swiss Society of Experimental Pharmacology (SSEP), 2005-2008
  • President, European Cell Death Society (ECDO), 2007-2009
  • President, Union of the Swiss Societies for Experimental Biology (USGEB / USSBE), 2007-2010
  • Member of the Scientific Commission, Swiss Cancer League, 2008-2017
  • Member of the Advisory Board, Helmholtz-Zentrum für Umweltforschung GmbH Leipzig (Germany), 2008-2012
  • Chairman of the Advisory Board, Helmholtz-Zentrum für Umweltforschung GmbH Leipzig (Germany), 2012-2014
  • Representative of the Mechanisms of Allergy/Asthma/Immunology (MAAI) section of the American Academy of Allergy, Asthma and Immunology (AAAAI), 2011-2015
  • Chair, committee “Cells and Cytokines” of the American Academy of Allergy, Asthma and Immunology (AAAAI), 2014-2016
    Member of the Council of the Collegium Internationale Allergologicum (CIA), 2010-2014
  • ERASMUS-Coordinator Pharmacology/Pharmacy, University of Bern, since 2011
  • Co-chair, Committee “Eosinophil, Mast Cell and Basophil Disorders in Allergic Disease”, World Allergy Organization (WAO), 2011-2015
  • Chairman of the Board of Trustees, Department of Clinical Research, Medical Faculty, University of Bern, 2012-2016
  • President, International Eosinophil Society (IES), 2013-2015
  • Vice-Chair, Immunopharmacology Section, International Union of Basic and Clinical Pharmacology (IUPHAR), since 2013
  • Chair, Task Force: Experimental Animal Center, University of Bern, 2013-2016
  • Member of the Scientific Executive Board of SystemsX.ch: The Swiss Initiative in Systems Biology, 2013-2016
  • Member of the Scientific Advisory Board of the Novartis Foundation, 2013-2017
  • Member of the Board of Directors, University Hospital Bern (Inselspital), 2016-2020
  • President, Collegium of the Deans of the Swiss Faculties of Medicine, 2018-2020
  • President, Scientific Advisory Board of the Novartis Foundation, since 2017
  • Panel Member, European Research Council (ERC), since 2019

Editorial Work in Scientific Journals:

1. APOPTOSIS Section Editor since 1996
2. INT. ARCH. ALLERGY IMMUNOL. Editorial Board 1998-2017
3. ALLERGY Advisory Board 1999-2002
4. ALLERGY Associate Editor 2003-2010
5. ALLERGOLOGIE Editorial Board since 1999
6. INT. J. HYG. ENVIRON. HEALTH Editorial Board since 2000
7. EXP. CLIN. ALLERGY Editorial Board 2001-2009
8. ALLERGO-JOURNAL Editorial Board since 2001
9. PLANTA MEDICA Advisory Board 2004-2006
10. J. ALLERGY CLIN. IMMUNOL. Editorial Board 2005-2010
11. CELL DEATH DIFFER. Section Editor since 2006
12. MOL. CELL. PHARMACOL. Editorial Board since 2008
13. ALLERGY Editor-in-Chief 2010-2018
14. CELL DEATH DISEASE Section Editor 2010-2016
15. FRONTIERS IN ONCOLOGY Associate Editor 2010-2019
16. CELL DEATH DISEASE Editor-in-Chief since 2016
17. J. IMMUNOLOGY Associate Editor since 2017
18. INT. ARCH. ALLERGY IMMUNOL. Editor-in-Chief since 2018
19. CELL DEATH DIFFER/DIS/DISCOV Ethics Committee since 2020
20. SEM. IMMUNOPATHOLOGY Guest Editor 2021

Selected Awards:

  • Paul Martini Prize, Paul Martini Foundation, Wiesbaden (D), April 1997
  • Georg Friedrich Götz Prize, University of Zurich, Medical Faculty, Zurich (CH), December 2000
  • Pfizer Research Prize, Zurich (CH), February 2003
  • Member of the German National Academy of Sciences Leopoldina, 2009
  • Member of the Swiss Academy of Medical Sciences, 2013
  • Doctor honoris causa, University of Ljubljana, December 2017
  • Phoenix Science Prize, November 2020
  • Doctor honoris causa, South Ural State Medical University, June 2021
Publikationen
Selected original publications: (h-index: 90; citations: 38’990; Scopus ID number: 7402135360; ORCID ID number: orcid.org/0000-0002-9404-7736)
 
1. H.-U. Simon, G.B. Mills, S. Hashimoto, K.A. Siminovitch:
Evidence for defective transmembrane signaling in B cells from patients with WiskottAldrich syndrome.
J. Clin. Invest. 90 (1992), 1396-1405.
 
2. S. Yousefi, D.R. Green, K. Blaser, H.-U. Simon:
Protein-tyrosine phosphorylation regulates apoptosis in human eosinophils and neutrophils.
Proc. Natl. Acad. Sci. USA 91 (1994), 10868-10872.
 
3. H.-U. Simon, S. Yousefi, C. C. Dommann-Scherrer, D. R. Zimmermann, S. Bauer, J. Barandun, K. Blaser:
Expansion of cytokine producing CD4-CD8- T cells associated with abnormal Fas expression and hypereosinophilia.
J. Exp. Med. 183 (1996), 1071-1082.
Comment in: J. Exp. Med. 183 (1996), 721-724 (Lenardo MJ)
 
4. S. Yousefi, D. C. Hoessli, K. Blaser, G. B. Mills, H.-U. Simon:
Requirement of Lyn and Syk tyrosine kinases for the prevention of apoptosis by cytokines in freshly isolated eosinophils.
J. Exp. Med. 183 (1996), 1407-1414.

5. M. Roth, M. Nauck, S. Yousefi, M. Tamm, K. Blaser, A.P. Perruchoud, H.-U. Simon:
Platelet-activating factor exerts mitogenic activity and stimulates expression of interleukin-6 and interleukin-8 in human lung fibroblasts via binding to its functional receptor.
J. Exp. Med. 184 (1996), 191-201.
 
6. H. Hebestreit, B. Dibbert, I. Balatti, D. Braun, A. Schapowal, K. Blaser, H.-U. Simon:
Disruption of Fas receptor signaling by nitric oxide in eosinophils.
J. Exp. Med. 187 (1998), 415-425.
 
7. H.-U. Simon, S. Yousefi, B. Dibbert, H. Hebestreit, D.R. Branch, K. Blaser, F. Levi-Schaffer, G.P. Anderson:
Role of tyrosine  phosphorylation and Lyn tyrosine kinase in Fas receptor-mediated apoptosis in eosinophils.
Blood 92 (1998), 547-557.
 
8. B. Dibbert, I. Daigle, D. Braun, C. Schranz, M. Weber, K. Blaser, U. Zangemeister-Wittke, A.N. Akbar, H.-U. Simon:
Role for Bcl-xL in delayed eosinophil apoptosis mediated by granulocyte-macrophage colony-stimulating factor and interleukin-5.
Blood 92 (1998), 778-783.
 
9. B. Dibbert, M. Weber, W.H. Nikolaizik, M.H. Schöni, P. Vogt, K. Blaser, H.-U. Simon:
Cytokine-mediated Bax deficiency associated with delayed neutrophil apoptosis in inflammation.
Proc. Natl. Acad. Sci. USA 96 (1999), 13330-13335.
 
10. H.-U. Simon, S.G. Plötz, R. Dummer, K. Blaser:
Abnormal clones of T cells producing interleukin 5 in idiopathic eosinophilia.
N. Engl. J. Med. 341 (1999), 1112-1120.
Comment in: N. Engl. J. Med. 341 (1999), 1141-1143 (Bain BJ)
Comment in: N. Engl. J. Med. 342 (1999), 659-660 (Guitart J)
Comment in: N. Engl. J. Med. 342 (1999), 660 (Roufosse F et al.)
Comment in: N. Engl. J. Med. 342 (1999), 660 (Suzuki R et al.)
 
11. I. Daigle, S. Yousefi, M. Colonna, D.R. Green, H.-U. Simon:
Death receptors bind SHP-1 and block cytokine-induced antiapoptotic signaling in neutrophils.
Nat. Med. 8 (2002), 61-67.
 
12. A. Straumann, H.P. Spichtin, L. Grize, K.A. Bucher, C. Beglinger, H.-U. Simon:
Natural history of primary eosinophilic esophagitis: A follow-up of 30 adult patients for up to 11.5 years.
Gastroenterology 125 (2003), 1660-1669.
Comment in: Gastroenterology 127 (2004), 364 (Langdon DE)

13. S.G. Plötz*, H.-U. Simon*, U. Darsow, D. Simon, E. Vassina, S. Yousefi, R. Hein, T. Smith, H. Behrendt, J. Ring:
Use of an anti-interleukin-5 antibody in the hypereosinophilic syndrome with eosinophilic dermatitis.
N. Engl. J. Med. 349 (2003), 2334-2339.
*Shared First-Authorship
 
14. F. Altznauer, S. Martinelli, S. Yousefi, C. Thürig, I. Schmid, E.M. Conway, M.H. Schöni, P. Vogt, C. Mueller, M.F. Fey, U. Zangemeister-Wittke, H.-U. Simon:
Inflammation-associated cell-cycle-independent block of apoptosis by survivin interminally differentiated neutrophils.
J. Exp. Med. 199 (2004), 1343-1354.
 
15. S. von Gunten, S. Yousefi, M. Seitz, S.M. Jakob, T. Schaffner, R. Seger, J. Takala, P.M. Villiger, H.-U. Simon:
Siglec-9 transduces apoptotic and nonapoptotic death signals into neutrophils depending on the pro-inflammatory cytokine environment.
Blood 106 (2005), 1423-1431.
 
16. S. von Gunten, A. Schaub, M. Vogel, B.M. Stadler, S. Miescher, H.-U. Simon:
Immunologic and functional evidence for anti-Siglec-9 autoantibodies in intravenous immunoglobulin (IVIg) preparations.
Blood 108 (2006), 4255-4259.
Comment in: J. Perinatology 27 (2007), 196-197 (Buenz EJ & Howe CL)
 
17. S. Yousefi, R. Perozzo, I. Schmid, A. Ziemiecki, T. Schaffner, L. Scapozza, T. Brunner, H.-U. Simon:
Calpain-mediated cleavage of Atg5 switches autophagy to apoptosis. Nat. Cell Biol. 8 (2006), 1124-1132.
Comment in: Nature Cell Biology 8 (2006), 1045-1047 (Codogno P & Meijer AJ)
Comment in: Nature Reviews Molecular Cell Biology 7 (2006), 796-797 (Heinrichs A)
 
18. S. Conus, R. Perozzo, T. Reinheckel, C. Peters, L. Scapozza, S. Yousefi, H.-U. Simon:
Caspase-8 is activated by cathepsin D initiating neutrophil apoptosis during the resolution of inflammation.
J. Exp. Med. 205 (2008), 685-698.
Comment in: Nature Reviews Immunology 8 (2008), 244 (Tufet M)
Comment in: J. Exp. Med. 205 (2008), 505 (Bashyam H)

19. S. Yousefi, J.A. Gold, N. Andina, J.J. Lee, A.M. Kelly, E. Kozlowski, I. Schmid, A. Straumann, J. Reichenbach, G.J. Gleich, H.-U. Simon: Catapult-like release of mitochondrial DNA by eosinophils contributes to antibacterial defense.
Nat. Med. 14 (2008), 949-953.
Comment in: Nature Medicine 14 (2008), 910-912 (Nizet V & Rothenberg ME)
Comment in: Nature Reviews Immunology 8 (2008), 658 (Leavy O)
Comment in: Science 321 (2008), 1021 (PAK)
Comment in: J. Allergy Clin. Immunol. 122 (2008), 661 (Gabbert S)
 
20. A. Straumann, S. Conus, P. Grzonka, H. Kita, G. Kephart, C. Bussmann, C. Beglinger, D.A. Smith, J. Patel, M. Byrne, H.-U. Simon: Anti-interleukin-5 antibody treatment (mepolizumab) in active eosinophilic oesophagitis: a randomized, placebo-controlled, double-blind trial.
Gut 59 (2010), 21-30.
 
21. A. Straumann, S. Conus, L. Degen, S. Felder, M. Kummer, H. Engel, C. Bussmann, C. Beglinger, A. Schoepfer, H.-U. Simon: Budesonide is effective in adolescent and adult patients with active eosinophilic esophagitis.
Gastroenterology 139 (2010), 1526-1537.
Comment in: Gastroenterology 139 (2010), 1429-1430 (Tack J and Carethers JM)
 
22. B. Geering, U. Gurzeler, E. Federzoni, T. Kaufmann, H.-U. Simon:
A novel TNFR1-triggered apoptosis pathway mediated by class IA PI3Ks in neutrophils.
Blood 117 (2011), 5953-5962.
 
23. S. Salemi, S. Yousefi, M.A. Constantinescu, M.F. Fey, H.-U. Simon:
Autophagy is required for self-renewal and differentiation of adult human stem cells.
Cell Res. 22 (2012), 432-435.
 
24. D. Maskey, S. Yousefi, I. Schmid, I. Zlobec, A. Perren, R. Friis, H.-U. Simon:
A novel role for ATG5 in drug-induced mitotic catastrophe independent of autophagy.
Nat. Commun. 4 (2013), 2130.
 
25. H. Liu, Z. He, T. von Rütte, S. Yousefi, R.E. Hunger, H.-U. Simon:
Downregulation of autophagy-related protein 5 (ATG5) contributes to the pathogenesis of early-stage cutaneous melanoma. Sci. Transl. Med. 5 (2013), 202ra123.
 
26. A. Soragni, S. Yousefi, C. Stoeckle, A.B. Soriaga, M.R. Sawaya, E. Kozlowski, I., Schmid, S. Radonjic-Hoesli, S. Boutet, G.J. Williams, M. Messerschmidt, M.M. Seibert, D. Cascio, N.A. Zatsepin, M. Burghammer, C. Riekel, J.-P. Colletier, R. Riek, D. Eisenberg, H.-U. Simon: Toxicity of eosinophil MBP is repressed by intracellular crystallization and promoted by extracellular aggregation.
Mol. Cell 57 (2015), 1011-1021.

27. S. Radonjic-Hoesli, X. Wang, E. de Graauw, C. Stoeckle, B. Styp-Rekowska, R. Hlushchuk, D. Simon, P.J. Spaeth, S. Yousefi, H.-U. Simon: Adhesion-induced eosinophil cytolysis requires the RIPK3-MLKL signaling pathway which is counter-regulated by autophagy. J. Allergy
Clin. Immunol. 140 (2017), 1632-1642.
Comment in: J. Allergy Clin. Immunol. 140 (2017), 1548-1549 (Renz H)
 
28. P. Amini, D. Stojkov, A. Felser, C.B. Jackson, C. Courage, A. Schaller, L. Gelman, M.E. Soriano, J.M. Nuoffer, L. Scorrano, C. Benarafa, S. Yousefi, H.-U. Simon: Neutrophil extracellular trap formation requires OPA1-dependent glycolytic ATP production.
Nat. Commun. 9 (2018), 2958.
 
29. H. Liu, Z. He, N. Germic, H. Ademi, Z. Frangez, A. Felser, J.-M. Nuoffer, C. Bovet, I. Mlinaric-Rascan, I. Zlobec, M. Fiedler, A. Perren, H.-U. Simon: ATG12 deficiency leads to tumor cell oncosis owing to diminished mitochondrial biogenesis and reduced cellular bioenergetics.
Cell Death Differ. 27 (2020), 1965-1980.
 
30. N. Germic, A. Hosseini, D. Stojkov, K. Oberson, M. Claus, C. Benarafa, S. Calzavarini, A. Angelillo-Scherrer, I.C. Arnold, A. Müller, C. Riether, S. Yousefi, H.-U. Simon: ATG5 promotes eosinopoiesis, but inhibits eosinophil effector functions.
Blood 137 (2021), 2958-2969.
 
31. T. Greuter, A. Straumann, Y. Fernandez-Marrero, N. Germic, A. Hosseini, S. Yousefi, D. Simon, M.H. Collins, C. Bussmann, M. Chehade, E.S. Dellon, G.T. Furuta, N. Gonsalves, I. Hirano, F.J. Moawad, L. Biedermann, E. Safroneeva, A.M. Schoepfer, H.-U. Simon: Characterization of eosinophilic esophagitis variants by clinical, histological and molecular analyses: a cross-sectional multicenter study.
Allergy 2021, in revision.